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end of IL7/placebo treatment was higher in the IL7-treated ani-
mals (122 vs 1/ml, p0.03). All animals were pretransplant cyto-
megalovirus seropositive. One animal died at the end of IL7 treat-
ment; necropsy showed extensive T cell inﬁltration of kidneys and
lungs. In conclusion, IL7 stimulates the expansion of CD4 T cells,
including functional anti-viral cells. Clinical risk:beneﬁt ratio
needs to be evaluated.
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DE NOVO GENERATION OF CD4 T CELLS AGAINST VIRUSES PRESENT
IN THE HOST DURING IMMUNE RECONSTITUTION
Kalina, T.; Lu, H.; Zhao, Z.; Kiem, H.-P.; Storek, J. Fred Hutchinson
Cancer Research Center and University of Washington, Seattle, WA.
Patients after hematopoietic cell transplantation lack naı¨ve T
cells because of insufﬁcient generation of T cells de novo (thymo-
poiesis). Ways to improve de novo generation have recently been
studied, using, e.g., prothymopoietic cytokines or a thymic or-
ganoid (“artiﬁcial thymus”). It is not known whether improved
thymopoiesis might result in more T cells only for pathogens that
are typically absent from the body (e.g., neopathogens like ebola
virus or cleared recall pathogens like measles virus) or also for
pathogens or malignant cells present in the body (e.g., herpesvi-
ruses that infected the host pretransplant or the leukemia that
necessitated hematopoietic cell transplantation). The latter T cells
may be more important, as posttransplant infections due to endog-
enous microorganisms (e.g., herpesviruses) and leukemic relapse
cause major morbidity and mortality. However, T cells recognizing
self-peptides should theoretically be deleted in the thymus by
negative selection. Peptides from the endogenous viruses or leu-
kemic cells might be considered by the thymus as self-peptides, and
T cells speciﬁc for these peptides might be deleted (negatively
selected). We demonstrated in four baboons infected with baboon
cytomegalovirus and baboon lymphocryptovirus (Epstein-Barr vi-
rus-like virus) that after autologous transplantation of yellow ﬂu-
orescent protein (YFP)-marked hematopoietic cells, YFP CD4 T
cells against these viruses were generated de novo. Thus the thymus
generates CD4 T cells against not only pathogens absent from the
host but also pathogens present in the host. This ﬁnding provides
a strong rationale to improve thymopoiesis in hematopoietic cell
transplant recipients.
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CROSS-REACTIVITY OF EPSTEIN BARR VIRUS-SPECIFIC CYTOTOXIC T
LYMPHOCYTES WITH A HLA-C LOCUS ALLELE
Keever-Taylor, C.A.; Ramadan, G.; Orental, R.J.; Davies, B.; Behn, B.;
Margolis, D.A. Medical College of Wisconsin, Milwaukee, WI.
The basis for T cell alloreactivity is thought to be primarily due
to cross-reactivity of antigen-speciﬁc T cells with Major Histo-
compatibility Complex alleles. The cross-reactivity of cytotoxic T
lymphocytes (CTL) from HLA-B8 individuals recognizing the
human herpesvirus IV (HHV4/EBV) FLRGRAYGL epitope en-
coded by the EBNA-3A latency antigen with self peptides pre-
sented on HLA-B4402, B35, and B14 are examples of this phe-
nomenon and may represent the mechanism by which herpes virus
infections augment graft vs host disease, allograft rejection and
autoimmunity. Here we describe an EBV-speciﬁc CTL line pre-
pared from a HLA-B8-negative haplo-identical parental hemato-
poietic progenitor cell donor to restore patient immunity to EBV,
that reacts strongly to non-EBV infected targets from the intended
recipient. The CTL line was primed 2 with donor-derived EBV-
transformed B lymphoblastoid cells lines (BLCL) at a responder:
stimulator ratio of 40:1 that was reduced to 4:1 at wk 3 with the
addition of IL-2 to the culture and was expanded to wk 5 at which
time it was tested for reactivity to donor BLCL and donor and
patient PHA blasts. The line showed potent reactivity to donor
BLCL (66.3% speciﬁc lysis at an effector:target ratio of 50:1), no
reactivity donor PHA blasts but unexpectedly, lysed patient PHA
blasts (41.6% at 50:1) in repeated assays. Screening of the line with
PHA blasts from individuals sharing one or two HLA alleles on the
mismatched patient haplotype revealed that lysis was directed to
HLA-C*0202. Screening of the EBV-CTL line with BLCL targets
from unrelated donors who shared donor HLA alleles but lacked
C*0202 showed that the line was partially HLA-restricted by
HLA-DQ-*0201, B*3701, B*0702, and C*0701. A new line from
the same donor primed for only two weeks with autologous BLCL
at a responder:stimulator ratio of 4:1 also showed strong reactivity
to donor BLCL and patient C*0202 PHA blasts. T cells produc-
ing IFN- in response to irradiated C*0202 PHA blasts were
selected from this line using a MACS column. Further character-
ization of the expanded MACS-selected CTL for EBV speciﬁc
antigen killing and HLA restriction is in progress. These data
further support cross-reactivity to peptide presented on self MHC
as the basis for T cell alloreactivity and illustrate the need for
careful screening of allo-EBV-CTL from HLA mismatched do-
nors with non-EBV infected patient targets to ensure that these
lines are safe to infuse into patients.
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CTL ACTIVITY OF IN VITRO-DERIVED MEMORY T CELLS IS MORE
EFFICIENT THAN NAI¨VE T CELLS IN SYNGENEIC RECIPIENTS IMMEDI-
ATELY FOLLOWING EXPERIMENTAL BMT
Roskos, M.; Levy, R.B. Department of Microbiology and Immunology,
University of Miami School of Medicine, Miami, FL.
We are interested in elucidating how transplanted memory CD8
T cells can contribute to the immune reconstitution of ablatively
conditioned BMT recipients. We have focused our studies on
memory CD8 T cells because they display more rapid, elevated
cytotoxicity compared to naı¨ve CD8 cells, and thus may make more
efﬁcient BMT adjuvants. A homogeneous TCR-transgenic (tg)
memory CD8 T population was generated in vitro and used in a
syngeneic murine BMT model to 1) investigate the homeostatic
proliferation and function of in vitro-derived memory T cells and
2) compare the CTL activity of these memory cells to that of naı¨ve
T cells in the reconstituting host. The in vitro-derived memory T
cell population (TM) was generated using either OT.I-RAG1/
or OT.I-GFP TCR tg mice. Brieﬂy, spleens from OT.I mice were
cultured for 3 days with rmIL-2 and OVA peptide, harvested, and
re-cultured for 2–4 days with rmIL-15. The resultant OT.I cells
expressed CD25lo, CD44hi, CD62L, and Ly6C, indicating a
central memory phenotype. The OT.I cells (1.5  106), together
with T cell-depleted B6 bone marrow (2  106), were transplanted
into 9.0 Gy-conditioned syngeneic recipients. Homeostatic prolif-
eration of TM was assessed by V5, GFP cell numbers in
recipient spleens 4 to 42 days post-BMT. TM expanded during the
ﬁrst 14 days (2 106/spleen) then maintained its number while the
spleen continued to increase for another two weeks. TM cell
number and phenotype remained unchanged90 days post-BMT.
CFSE-labeled OT.I-RAG1/ cells were used to precisely exam-
ine when, during the ﬁrst 2 weeks post-BMT, TM underwent
division. The ﬁrst several divisions were apparent as early as 3 days
post-BMT, and the TM population, as a whole, continued to
divide with 6 divisions observed by day 7. CTL function was
assessed within 14 days and then 28 days post-BMT using OVA-
pulsed targets. TM obtained from recipient spleens 7 days post-
BMT generated a more rapid, elevated CTL response compared to
transplanted naı¨ve OT.I cells (p 
 0.05). TM remained functional
at least 5 weeks post-BMT. In total, these ﬁndings demonstrate
that a homogeneous in vitro-derived memory CD8 T cell popula-
tion can efﬁciently expand and function immediately post-BMT.
Moreover, these memory CD8 T cells exhibit greater cytotoxic
activity compared to naı¨ve CD8 T cells, supporting the notion that
rapidly-generated, in vitro-derived memory CD8 T cells may have
the superior therapeutic potential immediately following BMT.
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RECONSTITUTION OF IMMUNITY TO ADENOVIRUS AFTER PEDIATRIC
BONE MARROW TRANSPLANT
Myers, G.D.; Leen, A.M.; Rooney, C.M.; Heslop, H.E.; Bollard, C.M.
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston,
TX; Department of Virology, Texas Childrens Hospital, Houston, TX;
The Methodist Hospital, Houston, TX.
Adenovirus has been shown to be a signiﬁcant cause of morbidity,
and mortality in the pediatric hematopoietic stem cell transplant
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